These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 642496)

  • 1. Study of sar-ala8 angiotensin II (saralasin) responsiveness in hypertension of renal origin.
    Arendell R; Lawson JD; Petracek MR; Meacham PW; Hollifield JW; Dean RH
    J Surg Res; 1978 Apr; 24(4):284-7. PubMed ID: 642496
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of administration of Sar1-Ala8-angiotensin II during the development and maintenance of renal hypertension in the rat.
    Fernandes M; Fiorentini R; Onesti G; Bellini G; Gould AB; Hessan H; Kim KE; Swartz C
    Clin Sci Mol Med; 1978 Jun; 54(6):633-7. PubMed ID: 657733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saralasin infusion in the recognition of renovascular hypertension.
    Wilson HM; Wilson JP; Slaton PE; Foster JH; Liddle GW; Hollifield JW
    Ann Intern Med; 1977 Jul; 87(1):36-42. PubMed ID: 879617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic studies of infusions with [Sar 1, Val5, Ala8] angiotensin II (saralasin).
    Gless KH; Bönner G; Gram N; Mann JF; Helber A; Ganten D
    Klin Wochenschr; 1978; 56 Suppl 1():97-105. PubMed ID: 732257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of renin-angiotensin system in experimental hypertension in rats: plasma renin and hypotensive effect of angiotensin II antagonist.
    Yamamoto J
    Jpn Circ J; 1977 Jun; 41(6):665-75. PubMed ID: 886656
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of saralasin on normal blood pressure and on reno-vascular hypertension (author's transl)].
    Beckerhoff R; Vetter W; Furrer J; Nussberger J; Schmied U; Siegenthaler W
    Dtsch Med Wochenschr; 1976 Mar; 101(11):398-401. PubMed ID: 1253700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximal discrimination of renovascular from essential hypertension by the saralasin test.
    Maxwell MH; Varady P; Zawada ET; Burkhalter JF; Waks U; Marks L
    Clin Sci Mol Med Suppl; 1978 Dec; 4():297s-299s. PubMed ID: 282071
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiotensin blockade in renovascular hypertension: a controlled, prospective study.
    Marks LS; Maxwell MH; Gross C; Waks U; Kaufman JJ
    Br J Urol; 1977 Jun; 49(3):181-8. PubMed ID: 334316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of adrenergic mediation of agonist response to [Sar1,Ala8]angiotensin II in conscious normotensive and hypertensive dogs.
    Zimmerman BG
    Clin Sci (Lond); 1979 Jul; 57(1):71-81. PubMed ID: 38941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of saralasin in end-stage renal disease.
    Fadem SZ; Lifschitz MD
    Kidney Int Suppl; 1979 Mar; (9):S93-100. PubMed ID: 289869
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative studies of the humoral and arterial pressure responses to Sar1-Ala8-, Sar1-Ile8 and Sar1-Thr8-angiotensin II in the trained unanaesthetized dog.
    Bravo EL; Khosla MC; Bumpus FM
    Prog Biochem Pharmacol; 1976; 12():33-40. PubMed ID: 1019168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of saralasin on plasma aldosterone in hypertensive man.
    Brown RD; Tucker R; Tue K; Wisgerhof M; Salassa R
    J Lab Clin Med; 1978 Mar; 91(3):473-9. PubMed ID: 627750
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo effects of angiotensin antagonists on plasma aldosterone in the dog.
    Beckerhoff R; Uhlschmid G; Furrer J; Nussberger J; Schmied UR; Vetter WJ; Siegenthaler W
    Eur J Pharmacol; 1975 Dec; 34(2):363-7. PubMed ID: 1234555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemodynamic effects of sar1-ala8-angiotensin in patients with renovascular hypertension (author's transl)].
    Philipp T; Zschierdrich H; Distler A
    Klin Wochenschr; 1977 Sep; 55(18):917-9. PubMed ID: 916618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of an angiotensin II antagonist (saralasin) as an adjunct during renal vein catheterization.
    Ibsen H; Giese J; Rabøl A; Kappelgaard AM
    Scand J Clin Lab Invest; 1980 Apr; 40(2):115-20. PubMed ID: 7020064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of angiotensin II blockade by saralasin (1-Sar-8-Ala-angiotensin II) in normal man.
    Ibsen H; Kappelgaard AM; Nielsen MD; Giese J
    Eur J Clin Pharmacol; 1978 Nov; 14(3):171-6. PubMed ID: 729612
    [No Abstract]   [Full Text] [Related]  

  • 18. [Saralasin test, renal vein renin and unilateral kidney blood flow in renovascular hypertension].
    Helber A; Hummerich W; Bönner G; Meurer KA; Moritz G
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():208-9. PubMed ID: 613575
    [No Abstract]   [Full Text] [Related]  

  • 19. Outpatient experience with saralasin.
    Streeten DH; Anderson GH
    Kidney Int Suppl; 1979 Mar; (9):S44-52. PubMed ID: 289863
    [No Abstract]   [Full Text] [Related]  

  • 20. [Significance of renin-angiotensin system inhibitors in the diagnosis of hypertension].
    Stumpe KO; Kolloch RE; Overlack A
    Med Welt; 1977 Oct; 28(41):1645-9. PubMed ID: 927124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.